Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib combined with chemotherapy for HER2-negative advanced breast cancer after standard therapy failure
ChiCTR2500103534Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib in breast cancer (2 cohorts), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500103534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103534.